Nupam P. Mahajan, PhD

Director of Urological Research

Washington University in St. Louis (WU)

Our group explores various epigenetic processes to identify precise signaling events that takes place in the cancer cells either during oncogenesis or upon exposure to various chemotherapeutic agents, including immune therapies (Mahajan et al., Nature Structural & Molecular Biology, 2012). To effectively overcome cancer cell proliferation, we have developed next generation of small molecule inhibitors (Mahajan et al., Cancer Cell, 2017), which are currently being evaluated in pre-IND studies with the goal of clinical trials in near future. Our inhibitors targeting ACK1 and WEE1 kinases have been highly promising in overcoming drug-resistant prostate and breast cancers. We have also developed a new class of immune modulators. For further information, visit our lab website: